Core Insights - Multiple myeloma, the second most common hematologic malignancy, has seen improved patient outcomes due to innovative therapies and standardized treatment protocols, allowing more patients to achieve long-term survival beyond five years [1] - The "2025 Meeting for Ten Years of New Life" event, initiated by Johnson & Johnson and supported by People's Good Doctor, highlighted the importance of deep remission and standardized management in achieving long-term survival for patients with hematologic cancers [1][3] Group 1 - The event showcased advancements in therapies such as monoclonal antibodies, bispecific antibodies, and CAR-T, which are transforming previously hard-to-treat malignancies into manageable chronic conditions [1] - Experts emphasized that achieving deep remission is crucial for long-term survival, which relies on regular follow-ups and standardized treatment [1] - The event included various activities like Qigong competitions and scientific dialogues, aimed at empowering patients and the medical community towards the goal of "functional cure" [1] Group 2 - The competition is the first of its kind in China focused on hematologic cancer patients, aligning with the "Healthy China" initiative to explore innovative rehabilitation paths that integrate traditional wellness with modern medicine [3] - Johnson & Johnson's commitment to patient health and innovative science was reiterated, with plans to deepen patient-centered chronic disease management models in China [3] - The Beijing event is a key part of a national series aimed at building a multi-layered disease management support ecosystem across regions [3]